[开放获取]    慢性自发性荨麻疹达标治疗专家共识（2023）

doi:10.35541/cjd.20230004

中华皮肤科杂志 ›› 2023, Vol. 56 ›› Issue (6): 489-495.doi: 10.35541/cjd.20230004

[开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会

收稿日期:2023-01-03 修回日期:2023-03-10 发布日期:2023-06-05
通讯作者: 肖汀；赵作涛；高兴华 E-mail:cmuxt@126.com; zhaozuotaotao@163.com; gaobarry@hotmail.com

Expert consensus on treat-to-target in chronic spontaneous urticaria （2023）

Chinese Society of Dermatology, China Dermatologist Association

Chinese Society of Dermatology, China Dermatologist Association

Received:2023-01-03 Revised:2023-03-10 Published:2023-06-05
Contact: Xiao Ting; Zhao Zuotao; Gao Xinghua E-mail:cmuxt@126.com; zhaozuotaotao@163.com; gaobarry@hotmail.com

摘要/Abstract

摘要： 【摘要】慢性自发性荨麻疹（CSU）是慢性荨麻疹中最常见的表型。标准剂量、加量或联合的二代抗组胺药是CSU的治疗选择，但约50%的患者对抗组胺治疗抵抗。达标治疗已被证实可提升慢性疾病的管理质量，但目前国内尚未提出CSU达标治疗的理念。我国荨麻疹诊疗及相关领域的31位专家基于国内外最新指南、共识及临床研究、真实世界研究进展，结合专家经验，共同制订CSU达标治疗共识，为临床医生提供指导。

关键词: 荨麻疹, 慢性自发性荨麻疹, 达标治疗, 专家共识

Abstract: 【Abstract】 Chronic spontaneous urticaria （CSU） is the most common phenotype of chronic urticaria. Liscenced-dosed, up-dosed, or combined second-generation H1-antihistamines are choices for the treatment of CSU. However, approximately 50% of patients with CSU are resistant to antihistamine therapies. The treat-to-target approach has been proven to improve the quality of chronic disease management, but has not been proposed in CSU in China so far. Based on the latest guidelines, consensus, clinical trials and real-world studies in China and other countries, and combined with experts′ clinical experience, 31 Chinese experts in the field of urticaria diagnosis and treatment and related fields developed this consensus on treat-to-target in CSU, aiming to provide detailed guidance to clinicians.

Key words: Urticaria, Chronic spontaneous urticaria, Treat-to-target, Consensus

中华医学会皮肤性病学分会中国医师协会皮肤科医师分会. [开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）[J]. 中华皮肤科杂志, 2023,56(6):489-495. doi:10.35541/cjd.20230004

Chinese Society of Dermatology, China Dermatologist Association. Expert consensus on treat-to-target in chronic spontaneous urticaria （2023）[J]. Chinese Journal of Dermatology, 2023, 56(6): 489-495.doi:10.35541/cjd.20230004

参考文献 48

［1］	Kolkhir P, Giménez⁃Arnau AM, Kulthanan K, et al. Urticaria［J］. Nat Rev Dis Primers, 2022,8（1）:61. doi: 10.1038/s41572⁃022⁃00389⁃z.
［2］	Zhao ZT, Ji CM, Yu WJ, et al. Omalizumab for the treatment of chronic spontaneous urticaria: a meta⁃analysis of randomized clinical trials［J］. J Allergy Clin Immunol, 2016,137（6）:1742⁃1750.e4. doi: 10.1016/j.jaci.2015.12.1342.
［3］	Maurer M, Weller K, Bindslev⁃Jensen C, et al. Unmet clinical needs in chronic spontaneous urticaria. A GA2LEN task force report［J］. Allergy, 2011,66（3）:317⁃330. doi: 10.1111/j.1398⁃9995.2010.02496.x.
［4］	Kim YS, Park SH, Han K, et al. Prevalence and incidence of chronic spontaneous urticaria in the entire Korean adult population［J］. Br J Dermatol, 2018,178（4）:976⁃977. doi: 10. 1111/bjd.16105.
［5］	Xiao Y, Huang X, Jing D, et al. The prevalence of atopic dermatitis and chronic spontaneous urticaria are associated with parental socioeconomic status in adolescents in China［J］. Acta Derm Venereol, 2019,99（3）:321⁃326. doi: 10.2340/00015555⁃3104.
［6］	于淼, 陈玉迪, 刘擘, 等. 中文版慢性荨麻疹生活质量问卷（CU⁃Q2oL）信效度验证［J］. 中华皮肤科杂志, 2020,53（12）:992⁃997. doi: 10.35541/cjd.20200091.
［7］	Dong W, An J, Geng P, et al. Years lost due to disability from skin diseases in China 1990⁃2017: findings from the Global Burden of Disease Study 2017［J］. Br J Dermatol, 2020,182（1）:248⁃250. doi: 10.1111/bjd.18329.
［8］	Huang Y, Xiao Y, Zhang X, et al. A meta⁃analysis of observational studies on the association of chronic urticaria with symptoms of depression and anxiety［J］. Front Med （Lausanne）, 2020,7:39. doi: 10.3389/fmed.2020.00039.
［9］	Kulthanan K, Chusakul S, Recto MT, et al. Economic burden of the inadequate management of allergic rhinitis and urticaria in Asian countries based on the GA2LEN model［J］. Allergy Asthma Immunol Res, 2018,10（4）:370⁃378. doi: 10.4168/aair.2018.10. 4.370.
［10］	Maurer M, Raap U, Staubach P, et al. Antihistamine⁃resistant chronic spontaneous urticaria: 1⁃year data from the AWARE study［J］. Clin Exp Allergy, 2019,49（5）:655⁃662. doi: 10.1111/cea.13309.
［11］	De Bruin⁃Weller M, Biedermann T, Bissonnette R, et al. Treat⁃to⁃target in atopic dermatitis: an international consensus on a set of core decision points for systemic therapies［J］. Acta Derm Venereol, 2021,101（2）:adv00402. doi: 10.2340/00015555⁃3751.
［12］	Gisondi P, Talamonti M, Chiricozzi A, et al. Treat⁃to⁃target approach for the management of patients with moderate⁃to⁃severe plaque psoriasis: consensus recommendations［J］. Dermatol Ther （Heidelb）, 2021,11（1）:235⁃252. doi: 10.1007/s13555⁃020⁃00475⁃8.
［13］	Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force［J］. Ann Rheum Dis, 2016,75（1）:3⁃15. doi: 10.1136/annrheumdis⁃2015⁃207524.
［14］	Parra Sánchez AR, Voskuyl AE, van Vollenhoven RF. Treat⁃to⁃target in systemic lupus erythematosus: advancing towards its implementation［J］. Nat Rev Rheumatol, 2022,18（3）:146⁃157. doi: 10.1038/s41584⁃021⁃00739⁃3.
［15］	赵作涛, 高兴华. 中重度特应性皮炎系统药物达标治疗专家指导建议［J］. 中国皮肤性病学杂志, 2022,36（8）:855⁃864. doi: 10.13735/j.cjdv.1001⁃7089.202205115.
［16］	Kolkhir P, Church MK, Weller K, et al. Autoimmune chronic spontaneous urticaria: what we know and what we do not know［J］. J Allergy Clin Immunol, 2017,139（6）:1772⁃1781.e1. doi: 10.1016/j.jaci.2016.08.050.
［17］	Yanase Y, Takahagi S, Ozawa K, et al. The role of coagulation and complement factors for mast cell activation in the pathogenesis of chronic spontaneous urticaria［J］. Cells, 2021,10（7）:1759. doi: 10.3390/cells10071759.
［18］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2018版）［J］. 中华皮肤科杂志, 2019,52（1）:1⁃5. doi: 10.3760/cma.j.issn.0412⁃4030.2019.01.001.
［19］	Zuberbier T, Abdul Latiff AH, Abuzakouk M, et al. The international EAACI/GA2LEN/EuroGuiDerm/APAAACI guideline for the definition, classification, diagnosis, and management of urticaria［J］. Allergy, 2022,77（3）:734⁃766. doi: 10.1111/all.15090.
［20］	Antia C, Baquerizo K, Korman A, et al. Urticaria: a comprehensive review: epidemiology, diagnosis, and work⁃up［J］. J Am Acad Dermatol, 2018,79（4）:599⁃614. doi: 10.1016/j.jaad.2018.01.020.
［21］	中华医学会皮肤性病学分会荨麻疹研究中心. 中国荨麻疹诊疗指南（2022版）［J］. 中华皮肤科杂志, 2022,55（12）:1041⁃1049. doi: 10.35541/cjd.20220609.
［22］	张敏, 崔振泽, 李悦, 等. 嗜碱性粒细胞活化试验在过敏性疾病应用中的研究进展［J］. 中国免疫学杂志, 2021,37（22）:2803⁃2809. doi: 10.3969/j.issn.1000⁃484X.2021.22.021.
［23］	Weller K, Groffik A, Church MK, et al. Development and validation of the Urticaria Control Test: a patient⁃reported outcome instrument for assessing urticaria control［J］. J Allergy Clin Immunol, 2014,133（5）:1365⁃1372, 1372.e1⁃6. doi: 10. 1016/j.jaci.2013.12.1076.
［24］	于淼, 陈玉迪, 刘擘, 等. 中文版荨麻疹控制评分量表及信效度验证［J］. 中华皮肤科杂志, 2020,53（7）:533⁃538. doi: 10. 35541/cjd.20191190.
［25］	Zhao Z, Zhang C, Jiang Y, et al. Chinese version of the chronic urticaria quality of life questionnaire: cultural adaptation, factor analysis, assessment of reliability and validity［J］. Arch Dermatol Res, 2022,314（9）:847⁃855. doi: 10.1007/s00403⁃021⁃02300⁃4.
［26］	Weller K, Groffik A, Magerl M, et al. Development, validation, and initial results of the Angioedema Activity Score［J］. Allergy, 2013,68（9）:1185⁃1192. doi: 10.1111/all.12209.
［27］	Weller K, Donoso T, Magerl M, et al. Validation of the Angioedema Control Test （AECT）⁃a patient⁃reported outcome instrument for assessing angioedema control［J］. J Allergy Clin Immunol Pract, 2020,8（6）:2050⁃2057.e4. doi: 10.1016/j.jaip. 2020.02.038.
［28］	Weller K, Groffik A, Magerl M, et al. Development and construct validation of the angioedema quality of life questionnaire［J］. Allergy, 2012,67（10）:1289⁃1298. doi: 10.1111/all.12007.
［29］	Finlay AY, Khan GK. Dermatology Life Quality Index （DLQI）⁃⁃a simple practical measure for routine clinical use［J］. Clin Exp Dermatol, 1994,19（3）:210⁃216. doi: 10.1111/j.1365⁃2230.1994.tb01167.x.
［30］	于淼, 陈玉迪, 刘擘, 等. 慢性自发性荨麻疹的临床评估体系［J］. 中华皮肤科杂志, 2021,54（12）:1117⁃1121. doi: 10.35541/cjd.20210379.
［31］	Simons FE, Simons KJ. Histamine and H1⁃antihistamines: celebrating a century of progress［J］. J Allergy Clin Immunol, 2011,128（6）:1139⁃1150.e4. doi: 10.1016/j.jaci.2011.09.005.
［32］	Yuan W, Hu S, Li M, et al. Efficacy and safety of omalizumab in Chinese patients with anti⁃histamine refractory chronic spontaneous urticaria［J］. Dermatol Ther, 2022,35（4）:e15303. doi: 10.1111/dth.15303.
［33］	Zhao Z, Cai T, Chen H, et al. Expert consensus on the use of omalizumab in chronic urticaria in China［J］. World Allergy Organ J, 2021,14（11）:100610. doi: 10.1016/j.waojou.2021.100610.
［34］	Chen Y, Yu M, Huang X, et al. Omalizumab treatment and outcomes in Chinese patients with chronic spontaneous urticaria, chronic inducible urticaria, or both［J］. World Allergy Organ J, 2021,14（1）:100501. doi: 10.1016/j.waojou.2020.100501.
［35］	Chen YD, Maurer M, Yu M, et al. Addition of omalizumab to antihistamine treatment in chronic urticaria: a real⁃world study in China［J］. Ann Allergy Asthma Immunol, 2020,125（2）:217⁃219. doi: 10.1016/j.anai.2020.04.026.
［36］	Khan DA, Kocatürk E, Bauer A, et al. What′s new in the treatment of urticaria and angioedema［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2170⁃2184. doi: 10.1016/j.jaip.2021.03.012.
［37］	He L, Yi W, Huang X, et al. Chronic urticaria: advances in understanding of the disease and clinical management［J］. Clin Rev Allergy Immunol, 2021,61（3）:424⁃448. doi: 10.1007/s12016⁃ 021⁃08886⁃x.
［38］	Türk M, Yılmaz İ, Şahiner ÜM, et al. Experience⁃based advice on stepping up and stepping down the therapeutic management of chronic spontaneous urticaria: where is the guidance?［J］. Allergy, 2022,77（5）:1626⁃1630. doi: 10.1111/all.15227.
［39］	Zhang L, Wu J, Qi Y, et al. Long⁃term combinations and updosing of second⁃generation H1⁃antihistamines show efficacy and safety in the treatment of chronic spontaneous urticaria: a multicenter real⁃life pilot study［J］. J Allergy Clin Immunol Pract, 2020,8（5）:1733⁃1736.e11. doi: 10.1016/j.jaip.2019.12.006.
［40］	Kulthanan K, Chaweekulrat P, Komoltri C, et al. Cyclosporine for chronic spontaneous urticaria: a meta⁃analysis and systematic review［J］. J Allergy Clin Immunol Pract, 2018,6（2）:586⁃599. doi: 10.1016/j.jaip.2017.07.017.
［41］	Song XT, Chen YD, Yu M, et al. Omalizumab in children and adolescents with chronic urticaria: a 16⁃week real⁃world study［J］. Allergy, 2021,76（4）:1271⁃1273. doi: 10.1111/all.14686.
［42］	Hansen C, Desrosiers TA, Wisniewski K, et al. Use of antihistamine medications during early pregnancy and selected birth defects: The National Birth Defects Prevention Study, 1997⁃2011［J］. Birth Defects Res, 2020,112（16）:1234⁃1252. doi: 10. 1002/bdr2.1749.
［43］	Namazy J, Cabana MD, Scheuerle AE, et al. The Xolair Pregnancy Registry （EXPECT）: the safety of omalizumab use during pregnancy［J］. J Allergy Clin Immunol, 2015, 135（2）:407⁃412. doi: 10.1016/j.jaci.2014.08.025.
［44］	Liao SL, Yu M, Zhao ZT, et al. Case report: omalizumab for chronic spontaneous urticaria in pregnancy［J］. Front Immunol, 2021,12:652973. doi: 10.3389/fimmu.2021.652973.
［45］	Kocatürk E, Podder I, Zenclussen AC, et al. Urticaria in pregnancy and lactation［J］. Front Allergy, 2022,3:892673. doi: 10.3389/falgy.2022.892673.
［46］	Kulthanan K, Rujitharanawong C, Munprom K, et al. Prevalence, clinical manifestations, treatment, and clinical course of chronic urticaria in elderly: a systematic review［J］. J Asthma Allergy, 2022,15:1455⁃1490. doi: 10.2147/JAA.S379912.
［47］	Longhurst HJ, Gonçalo M, Godse K, et al. Managing chronic urticaria and recurrent angioedema differently with advancing age［J］. J Allergy Clin Immunol Pract, 2021,9（6）:2186⁃2194. doi: 10.1016/j.jaip.2021.03.034.
［48］	陈玉迪, 胡艳, 隋海晶, 等. 抗IgE单克隆抗体在变态反应性疾病治疗中的应用［J］. 中华临床免疫和变态反应杂志, 2018,12（3）:302⁃307. doi: 10.3969/j.issn.1673⁃8705.2018.03.008.

[1]	陈奇权杨显杰顾恒徐金华郝飞姚煦宋志强. [开放获取] 基于德尔菲法构建《中国慢性诱导性荨麻疹诊治专家共识（2023）》[J]. 中华皮肤科杂志, 2023, 56(6): 534-539.
[2]	中华医学会皮肤性病学分会免疫学组. [开放获取] 中国慢性诱导性荨麻疹诊治专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(6): 479-488.
[3]	梁云生黎展宏伍奕蓓. [开放获取] 从发病机制认知变化看慢性自发性荨麻疹治疗进展[J]. 中华皮肤科杂志, 2023, 56(6): 552-558.
[4]	张立明肖汀. 慢性自发性荨麻疹的自身免疫发病机制研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 567-570.
[5]	杨娜丽许秋阳吴含文叶雅慧朱吉玲刘晶晶李智铭. [开放获取] 奥马珠单抗治疗慢性荨麻疹的疗效和安全性回顾性分析[J]. 中华皮肤科杂志, 2023, 56(6): 518-524.
[6]	陈奇权孔敏敏杨显杰王欢李健张名望宋志强. [开放获取] 慢性诱导性荨麻疹患者168例过敏原反应性和特应性病史的临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 496-503.
[7]	苏畅隋秀丽刘瑞玲曹毅群姜虹严彩蓉王惠平亓玉青. [开放获取] 奥马珠单抗治疗慢性自发性荨麻疹伴有其他过敏性疾病患者74例临床分析[J]. 中华皮肤科杂志, 2023, 56(6): 512-517.
[8]	王鑫刘丽娟李邻峰. [开放获取] 我国慢性自发性荨麻疹临床特征：基于多家医院问卷调查的流行病学研究[J]. 中华皮肤科杂志, 2023, 56(6): 525-530.
[9]	李丽俏彭聪陈翔李捷. [开放获取] 奥马珠单抗治疗对抗组胺药反应不佳的慢性荨麻疹患者单中心回顾性研究[J]. 中华皮肤科杂志, 2023, 56(6): 504-511.
[10]	陈奇权杨显杰王文稳梁高澎宋志强. 胆碱能性荨麻疹临床评估工具的开发及应用进展[J]. 中华皮肤科杂志, 2023, 56(6): 563-566.
[11]	焦晴晴张晓艳季江. 慢性自发性荨麻疹活动度相关生物学指标的研究进展[J]. 中华皮肤科杂志, 2023, 56(6): 559-562.
[12]	《蕈样肉芽肿治疗中国专家共识》编写专家组. [开放获取] 蕈样肉芽肿治疗中国专家共识（2023）[J]. 中华皮肤科杂志, 2023, 56(5): 402-409.
[13]	杨晓静陈雷刚王世宁吴远慧朱由瑾安国芝周向昭孟昭影. 慢性自发性荨麻疹患者血清白细胞介素9、血小板活化因子水平与总IgE、病情严重程度和病程的相关性研究[J]. 中华皮肤科杂志, 2023, 56(4): 337-341.
[14]	中华医学会皮肤性病学分会银屑病专业委员会. 银屑病生物制剂达标治疗专家共识[J]. 中华皮肤科杂志, 2023, 56(3): 191-203.
[15]	于淼宋晓婷刘擘廖双璐栾婷婷赵作涛. 慢性自发性荨麻疹患者自体血清皮肤试验的免疫学机制及与临床特征和预后的关系[J]. 中华皮肤科杂志, 2023, 56(2): 184-187.

[开放获取] 慢性自发性荨麻疹达标治疗专家共识（2023）

Expert consensus on treat-to-target in chronic spontaneous urticaria （2023）

PDF

PDF (Mobile)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 48

相关文章 15

Metrics

本文评价

推荐阅读 10